NCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
19 trialsNCT06136897 2026-03-18
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06649331 2026-03-17
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Fudan University
Phase 2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04886531 2026-03-12
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07102381 2026-03-12
EmpowHER 208
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05672524 2026-03-04
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04266249 2026-03-02
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05325632 2026-03-02
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07053085 2026-02-27
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07421141 2026-02-27
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Active not recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT06100874 2026-02-24
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT06016387 2026-02-23
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT01853748 2026-02-19
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
Phase 2 Completed